Hydrix Wins Singapore Heart Centre as Remote Monitoring Customer

Hydrix Limited (ASX:HYD) has won a three-year contract with one of Asia’s leading cardiovascular institutions, giving its medical technology arm a new reference customer for remote cardiac monitoring in the region. The agreement with Singapore’s National Heart Centre is estimated to be worth approximately A$0.625 million, subject to the number of patients monitored.

Three-Year Contract Adds Recurring Revenue

Hydrix Medical will deploy Implicity’s cloud-based platform at the National Heart Centre Singapore, or NHCS. The company has indicated annual recurring revenue of about A$0.21 million over the agreed three-year term, with revenue flowing to Hydrix upon implementation.

That timing makes the near-term commercial milestone implementation rather than contract signature. The announcement says deployment is expected to begin shortly, but does not provide a specific start date. Patient numbers and pricing remain commercially confidential, leaving the A$0.625 million figure as an estimate rather than a fixed commitment.

Implicity Connects Multiple Cardiac Devices

The platform is designed to aggregate and standardise data from cardiac implantable electronic devices made by different manufacturers. Those devices include pacemakers, implantable cardioverter defibrillators and cardiac resynchronisation therapy systems.

For clinicians, the stated proposition is a single interface that can streamline monitoring workflows and support earlier intervention through analytics. Implicity also conducts research and development into AI-based algorithms, although this contract announcement does not quantify any clinical or operational outcomes from the NHCS deployment.

Singapore Site to Support Regional Expansion

NHCS is Singapore’s national and regional referral centre for cardiovascular disease and a member of SingHealth. Hydrix Medical described the institution’s selection of Implicity as validation of its Asia-Pacific growth strategy and said it intends to use the site as a reference customer when pursuing opportunities in Singapore, Australia and the broader region.

That creates a second potential payoff beyond the disclosed contract value: whether a recognised hospital customer helps Hydrix convert further prospects. The filing does not disclose a pipeline, target number of new sites or timeframe for any additional contracts, so the expansion case remains dependent on future sales rather than this agreement alone.

Implementation and Patient Volumes Are the Next Tests

The immediate questions are how quickly the platform goes live and how many patients are ultimately monitored. Those factors will determine the revenue realised under the agreement and whether the recurring revenue estimate translates into reported results.

For Hydrix shareholders, the contract is a positive commercial development with a defined multi-year revenue stream, but its scale should be kept in proportion: the disclosed value is estimated, patient-dependent and modest enough that execution will matter more than the headline announcement.